Study on the Tumor-Inhibiting Effect of Deliping Oral Solution on Liver Cancer and Its Synergistic Effect in Enhancing Efficacy and Reducing Toxicity When Combined with 5-F

Zhang Guoyuan; Xie Banghe; Wang Tan; Gao Rui

doi:10.3969/j.issn.1004-3403.2025.03.010

Abstract：Objective To preliminarily explore the tumor-inhibiting effect of Deliping Oral Solution on the human liver cancer Bel-7402 cell line and its synergisticeffect when combined with 5-FU in enhancing efficacy and reducing toxicity in the treatment of H22 liver cancer cell transplantation tumors in mice.Methods:Tumor-inhibiting experi-mental Methods Human liver cancer Bel-7402 tumor tissue blocks,which had been passaged and grown well in the nude mice,were subcutaneously inoculated into the right axilla of BALB/C nude mice.Once the tumors reached a visible and palpable state,the animals were randomly divided into 6 groups,with 10 animals in each group,namely,a blank control group for oral solution,a blank control group for physiological injection saline,a positive control group for Delisheng Injection(2.14 g/kg),and low-、medium-、and high-dose groups of Deliping Oral Solution(2.5 g/kg、4.0 g/kg、8.0 g/kg).Administration lasted for 24 days.Subcutaneous tumor volumes were seasured to plot tu-mor growth curves.Tumors were weighed to calculate the tumor growth inhibition rate.Experimental method for en-hancing efficacy and reducing toxicity when combined with 5-FU:Subcutaneous inoculation of mouse transplanted tumor strain liver cancer 22(H22)tumor tissue,which had been passaged or preserved in liquid nitrogen,was per-formed on the right axilla of KM mice.After vaccination,the animals were randomly divided into 7 groups,with 10 animals in each group,namely,Group A:blank control group,water,20 mL/kg,i.g.(intragastric gavage);Group B:5-FU 12.5 mg/kg,i.p.(intraperitoneal injection);Group C:5-FU 25.0 mg/kg,i.p.;Group D:5-FU 50.0mg/kg,i.p.;Group E:Deliping Oral Solution 2.5 g i.g.+5-FU 12.5 mg i.p.;Group F:Deliping Oral Solution 4.0 g i.g.+5-FU 25.0mg i.p.;Group G:Deliping Oral Solution 8.0 g i.g.+5-FU 50 mg i.p..Tumor-bearing mice were administered once a day for 10 consecutive days.Measured indicators included body weight,tumor weight,tumor inhibition rate,and white blood cell count.The experiment was repeated twice.Results Deliping Oral Solution exhibited tumor-inhibit-ing activity against human liver cancer Bel-7402.The tumor inhibition rate of Delisheng Injection group(2.14 g/kg)was 49.51％,which was significantly different from the control group(P<0.01).The inhibition rate of Deliping Oral Solution in the medium-and high-dose groups(24.0 g/kg、8.0 g/kg)were 45.63％and 46.6％,respectively,which had a significant tumor-inhibiting effect(P<0.01).There was no significant difference in tumor inhibition rate between the medium-and high-dose groups of Deliping Oral Solution and the Delisheng Injection group.The combination of high-dose group of Deliping Oral Solution and high-dose group of 5-FU showed an average inhibition rate of 55.38％and 78.98％on H22 mice,respectively,with a statistical difference(P<0.05,P<0.001)compared to the high-dose group of 5-FU alone.The weight gain in 5-FU high-dose group alone(50.0 mg/kg)was significantly lower than that in the high-dose group of 5-FU(50 mg/kg)combined with Deliping Oral Solution(8.0 g/kg),with a statistical differ-ence(P<0.05)between the two groups.The total number of white blood cells in the high-dose group of 5-FU(50 mg/kg)combined with Deliping Oral Solution(8.0 g/kg)was significantly higher than that in the 5-FU chemotherapy group alone,with a statistical difference(P<0.05)between the two groups.Conclusion Delipin Oral Solution exhib-its a significant tumor-inhibiting effect on liver cancer Bel-7402,with a certain dose-effect relationship.When com-bined with the chemotherapy drug 5-F,it shows a notable synergistic effect in enhancing efficacy and reducing toxici-ty in mice transplanted with H22 tumors.